'26

Crescent
PHARMA LIMITED

Key House, Sarum Hill, Basingstoke, RG21 8SR, UK |
www.crescentpharma.com | 01256 772730

CARBON REDUCTION PLAN

Reporting company	Crescent Pharma Limited
Company number	04750933
Registered address	Key House, Sarum Hill, Basingstoke, Hampshire, RG21 8SR
Sector	Generic Pharmaceuticals — marketing authorisation holding, importation, batch certification and wholesale distribution
Revision / publication date	Revision 05 / September 2026
Baseline period	1 January 2024 to 31 December 2024
Current reporting period	1 January 2025 to 31 December 2025

Company Overview

Crescent Pharma Limited is a UK pharmaceutical company engaged in the development and supply of generic medicines. Its activities include marketing authorisation holding, importation, batch certification, wholesale distribution and associated commercial, quality and regulatory functions. The Company's registered office is at Key House, Sarum Hill, Basingstoke, Hampshire, RG21 8SR.

This Carbon Reduction Plan relates to Crescent Pharma Limited, company number 04750933, and is not a consolidated Carbon Reduction Plan for Crescent Pharmaceutical Group. References to the Company throughout this document mean Crescent Pharma Limited only.

The operations included in each reporting period are identified in the reporting-boundary and site records supporting this plan. Activities and facilities operated by other group companies are not presented as Crescent Pharma Limited's own operations merely because they share ownership, branding or services.

Crescent Pharma Limited holds an MHRA approved Manufacturers/Importers Authorisation (MIA), Wholesale Distribution Authorisation (WDA) and over 800 UK Marketing Authorisations (MAs). Head office is based in Basingstoke with multiple satellite offices in the south of the UK. This Carbon Reduction Plan covers Crescent Pharma Limited's operations and relevant value-chain emissions within the organisational boundary defined in this plan, including applicable overseas supply-chain and logistics emissions attributable to the Company.

Commitment to Achieving Net Zero

Crescent Pharma Limited is committed to achieving net zero greenhouse gas emissions by 2050 at the latest.

This commitment applies to the whole of Crescent Pharma Limited, including its operations and relevant value-chain emissions worldwide, within the organisational boundary defined in this plan. It does not represent the emissions or commitments of other group companies as Crescent Pharma Limited's own.

The Company will prioritise reductions in energy demand, fuel use, purchased goods, transport and waste. Gross emissions will be reported before carbon credits or offsets. Any future use of credits or removals will be disclosed separately and will not be presented as a reduction in the gross emissions inventory.

Baseline Review and Restatement

As part of the preparation of this 2026 Carbon Reduction Plan, covering the 2025 reporting year, Crescent Pharma Limited completed a detailed review of the methodology, reporting boundary and supporting data used to prepare its previously published 2024 emissions baseline.

The review identified that the historic calculation had been prepared using broader Group-level information and higher-level assumptions that did not sufficiently distinguish emissions specifically attributable to Crescent Pharma Limited. It also relied more extensively on broad proxy calculations rather than activity data directly linked to Crescent Pharma Limited's operations.

Crescent Pharma Limited has therefore restated its 2024 baseline.

The restated baseline applies a company-specific organisational boundary and recalculates both the 2024 baseline and 2025 reporting year using a consistent methodology based upon the principles of the Greenhouse Gas Protocol Corporate Accounting and Reporting Standard and Corporate Value Chain (Scope 3) Standard.

The revised methodology makes greater use of company-specific activity data, including utility consumption, vehicle activity, logistics volumes, pallet movements, geographic sourcing information and the operational structure of Crescent's UK distribution network.

The resulting change from the previously published 2024 figures represents a restatement arising from improvements in organisational boundary, source data and calculation methodology. It does not represent an operational reduction in greenhouse gas emissions and has not been treated as a carbon reduction achievement.

Emissions source	**Restated 2024 baseline (tCO_2e)**	**2025 reporting year (tCO_2e)**
Scope 1	137.72	134.44
Scope 2	181.01	178.20
Scope 3 – Upstream transportation and distribution	6,006.10	5,981.16
Scope 3 – Waste generated in operations	29.63	29.63
Scope 3 – Business travel	47.40	47.40
Scope 3 – Employee commuting	30.00	30.00
Scope 3 – Downstream transportation and distribution	10.00	10.00
Total Scope 3 emissions	6,123.13 tCO_2e	6,098.19 tCO_2e
Total emissions	**6,441.86**	**6,410.83**

The Scope 3 emissions reported above comprise the five Scope 3 categories required under PPN 006 and do not yet represent a complete 15-category Scope 3 inventory. Crescent Pharma Limited will complete its assessment of all 15 Scope 3 categories by 31 March 2027 and publish any update required to meet the applicable 2027 NHS Carbon Reduction Plan requirements. The completed 2026 annual emissions inventory and next full annual Carbon Reduction Plan will be published by 30 June 2027.

On the restated and consistently calculated basis, total reported emissions decreased by approximately 31.03 tCO_2e, or 0.48%, between 2024 and 2025.

The reduction is modest and is principally associated with changes in Crescent Pharma Limited's distribution model, including a reduction in intersite stock transfers during 2025. The Company has not attributed the movement solely to carbon-reduction initiatives, as emissions are also influenced by operational activity, distribution patterns and annual greenhouse gas conversion factors.

Calculation Methodology and Data Quality

The inventory is prepared using the GHG Protocol Corporate Accounting and Reporting Standard, the Corporate Value Chain (Scope 3) Standard, the applicable Scope 2 Guidance and the PPN 006 reporting standard.

Company-specific meter readings, invoices, fuel records, refrigerant records, shipment data, waste records, travel records and employee information are used where available. Estimates are identified separately with their source, allocation method, assumptions and limitations. A benchmark or expenditure-based estimate is not described as measured consumption.

Conversion factors are selected for the activity, geography and reporting period. For UK activity, the 2024 and 2025 Government GHG Conversion Factors are used for the respective years where appropriate. Other factors are separately identified, including the database, version, geography, currency and price-year adjustments. Finance will reconcile source information to Crescent Pharma Limited’s legal-entity records, including procurement and intercompany ledgers, payroll, assets, leases and utility charges. Group SECR totals and group headcount will not be treated as standalone company data without an evidenced boundary reconciliation.

Freight and storage purchased by the Company, including purchased outbound and inter-site services, are assessed in Scope 3 Category 4. Category 9 covers relevant onward distribution and storage not purchased by the Company.

Employee commuting calculations use Crescent Pharma Limited’s reporting-year workforce, travel modes, return distances and attendance patterns, with explained survey extrapolation. Operational waste calculations use material type, weight and treatment route; financial stock write-offs are not treated as waste mass.

Carbon Reduction Targets

Crescent Pharma Limited adopts the following company-specific targets and delivery milestones. Progress will be measured against the Company’s validated baseline and reported annually.

Target	Company-specific commitment
Net zero	Achieve net zero across the Company’s Scope 1, Scope 2 and relevant Scope 3 emissions by 2050 at the latest.
Absolute operational reduction	Reduce combined Scope 1 and location-based Scope 2 emissions by at least 25% by 31 December 2035 against the validated 2024 baseline. Market-based results will be reported separately.
Renewable electricity	Achieve at least 10% renewable electricity by 2029, at least 50% by 2035 and 100% by 2050. Progress will be measured using evidenced renewable electricity consumed as a proportion of total electricity consumed, not the percentage of sites.

Acceleration review	By 31 March 2027, complete a costed assessment of achieving 100% qualifying renewable electricity on directly controlled contracts by 2030. Publish the approved outcome and separately address landlord-controlled supplies.
Additional near-term targets	By 31 March 2027, approve additional 2030 operational and material Scope 3 milestones supported by action plans and defined calculation methods.
Scope 3 coverage	Screen all 15 categories by 31 December 2026 and prepare the applicable expanded company-level reporting before 1 April 2027.
Annual reporting	Review performance quarterly and publish the completed 2026 inventory and next annual CRP by 30 June 2027.

The renewable-electricity milestones are enabling measures, not substitutes for the absolute emissions target. Targets will be supported by costed projects and reviewed at least every three years, or sooner following material changes in the business, evidence or customer requirements.

The Company does not claim that its targets have been independently validated unless separate verification is disclosed.

Organisational boundary

The emissions inventory has been prepared for Crescent Pharma Limited, being the supplier entity to which the Carbon Reduction Plan relates. This represents a refinement from the methodology supporting the previously published baseline, which incorporated broader Group-level data and assumptions.

The revised approach is intended to ensure that emissions included within the Carbon Reduction Plan are attributable to the activities and operations of Crescent Pharma Limited and can be reproduced consistently in future reporting periods.

Where services are purchased from other Group companies or third parties, the resulting emissions are considered within the appropriate Scope 3 category rather than treating the direct operational emissions of those separate entities as Crescent Pharma Limited Scope 1 or Scope 2 emissions.

Crescent Pharma Limited applies the operational control approach under the Greenhouse Gas Protocol in defining its organisational boundary. Greenhouse gas emissions are reported in tonnes of carbon dioxide equivalent (tCO_2e) and cover the seven greenhouse gases specified by the applicable Carbon Reduction Plan reporting standard, where relevant to the Company's activities.

Scope 1 methodology

Scope 1 includes emissions arising from natural gas consumption, company-controlled vehicles and estimated fugitive refrigerant emissions. Natural gas consumption and vehicle emissions have been calculated using the available Crescent Pharma Limited activity records.

Where complete equipment-level refrigerant records were not available, refrigerant emissions have been estimated using a documented screening methodology for stationary air-conditioning equipment. The estimate uses a medium-range equipment charge and leakage assumption and is applied consistently between reporting periods. Estimated refrigerant emissions included within Scope 1 are approximately 12.59 tCO_2e per annum.

Scope 2 methodology

Scope 2 emissions have been calculated from electricity consumed within Crescent Pharma Limited's reporting boundary. Electricity consumption has been derived from the available supplier invoices, meter information and reconciled billing records. Where billing periods crossed reporting-year boundaries, consumption has been allocated to the appropriate reporting period.

The applicable UK Government greenhouse gas conversion factor for the relevant reporting year has been used to calculate location-based Scope 2 emissions.

Scope 3 – transportation and distribution

Transportation and distribution represent the most significant component of Crescent Pharma Limited's reported Scope 3 footprint.

The historic calculation has been replaced by a more detailed activity-based distance methodology, based on the quantity of goods transported, estimated shipment weight, transport distance and mode.

The calculation follows the Greenhouse Gas Protocol distance-based methodology:

Weight transported × distance travelled × applicable transport-mode emissions factor.

UK Government greenhouse gas conversion factors applicable to each reporting year have been used. For Scope 3 transportation, the calculation incorporates the relevant freight and upstream fuel components to provide a life-cycle transport emissions estimate consistent with the Greenhouse Gas Protocol Scope 3 calculation guidance.

Inbound transportation

The 38,000 annual inbound pallets have been allocated according to Crescent Pharma Limited's estimated product sourcing profile. Representative sea and road distances have then been applied to each geographic sourcing route.

Outbound transportation

Crescent Pharma Limited pays for its principal outbound customer distribution. In accordance with the Greenhouse Gas Protocol, purchased outbound transportation services are therefore included within Scope 3 Category 4 – Upstream Transportation and Distribution, notwithstanding that the physical movement is downstream of Crescent's premises.

Scope 3 Category 9 therefore captures only relevant downstream transportation and distribution that occurs beyond the transportation services purchased by Crescent Pharma Limited.

Intersite stock transfers

Crescent's historic distribution structure also resulted in stock being transferred between storage and distribution locations before final customer dispatch. These movements are additional to the principal inbound and outbound pallet activity.

For the restated 2024 baseline, intersite activity has been estimated at approximately 30% of principal pallet movements, representing approximately 21,600 additional pallet movements.

For 2025, this allowance has been reduced to approximately 20%, representing approximately 14,400 additional pallet movements.

The change reflects the evolution of Crescent's distribution model. During 2024, a greater proportion of inventory was transferred between locations prior to customer dispatch. During 2025, following the acquisition and development of the Sheffield distribution operation and increased direct dispatch from local sites and third-party locations, fewer internal stock transfers were required before customer delivery.

Intersite movements have been calculated as UK road freight using the same average pallet-weight methodology and a representative average road distance. They have not been calculated as a percentage uplift to international freight emissions, because doing so would incorrectly attribute international shipping distances and carbon intensity to domestic stock movements.

Estimated Category 4 emissions are therefore:

- 2024: 6,006.10 tCO_2e
- 2025: 5,981.16 tCO_2e

The reduction in intersite movements offsets the increase arising from changes in annual freight conversion factors and results in a modest reduction in total Category 4 emissions between the two reporting periods.

Other Scope 3 emissions

Where sufficiently complete primary activity data was not available for the remaining required Scope 3 categories, Crescent Pharma Limited has applied documented proxy estimates using the best information reasonably available.

The following emissions have been included:

- Waste generated in operations – 29.63 tCO_2e
- Business travel – 47.40 tCO_2e
- Employee commuting – 30.00 tCO_2e
- Downstream transportation and distribution not paid for by Crescent – 10.00 tCO_2e

The same proxy basis has been applied to 2024 and 2025 where there is insufficient primary evidence to demonstrate a reliable year-on-year change. This avoids recognising an unsupported emissions improvement or deterioration.

Crescent intends to progressively replace these proxy calculations with improved primary activity information where reasonably available.

Basis of the restatement

Crescent Pharma Limited's previously published 2024 Carbon Reduction Plan reported total emissions of **23,356.03 tCO_2e**.

The restated PPN 006 reporting baseline is **6,441.86 tCO_2e**.

The difference of approximately **16,914.17 tCO_2e** is a reporting restatement and does **not** represent a 72.4% operational reduction in emissions.

The principal reasons for the difference are:

- correction of the organisational boundary from broader Group-level information to Crescent Pharma Limited;
- replacement of broad historical assumptions with company-specific utility and operational data;
- correction and reconciliation of identified utility and classification issues;
- introduction of an activity-based freight calculation using pallet volumes, product sourcing, distance and mode;
- explicit recognition of intersite stock-transfer activity;
- consistent treatment of Crescent-paid inbound and outbound transportation within Scope 3 Category 4; and
- alignment of the reported footprint with the Scope 1, Scope 2 and required Scope 3 categories applicable to the Carbon Reduction Plan.

The previously published total also contained additional Scope 3 information that is not part of the minimum five Scope 3 categories required under the current PPN 006 Carbon Reduction Plan reporting boundary. These additional categories should therefore not be directly compared with the restated mandatory CRP footprint without first being recalculated using the same Crescent Pharma Limited organisational boundary and methodology.

The restated 2024 baseline has therefore been established as the appropriate comparator for measuring Crescent Pharma Limited's future emissions performance.

Data quality and future improvement

Crescent Pharma Limited has used the best and latest information reasonably available at the date of preparation.

Where primary activity information is available, it has been used in preference to generic financial or Group-level proxies. Where primary information remains incomplete, reasonable estimates have been applied and the principal assumptions have been documented.

The Company will continue to improve the quality of its greenhouse gas inventory by obtaining, where available, actual carrier tonnage and route information, more detailed intersite movement records, supplier carbon information, refrigerant service records, waste tonnage, business travel activity and employee commuting information.

The methodology adopted for the restated 2024 baseline and 2025 reporting year is intended to provide a consistent and reproducible basis for future Carbon Reduction Plans.

Current Environmental Measures and Ongoing Programmes

Crescent Pharma Limited’s environmental programme is supported by the Social and Environmental Policy, CORP-POL-00057, Revision 02. The measures below include established practices together with active improvement programmes that are in progress or approved for delivery.

The implementation register records the measures actually in effect or in approved delivery at the publication date. It distinguishes implementation from intended outcomes. Measures within the Company’s control will be applied, where relevant, to the performance of NHS and other public-sector medicine-supply contracts.

A measure will not be described as completed until its implementation record supports that description. Quantified savings will be reported only where the Company can identify the baseline, reporting period, boundary and calculation method. Where savings have not yet been quantified, the measure will be described without a numerical reduction claim.

Responsible Sourcing and Supplier Environmental Controls

Crescent Pharma Limited will incorporate proportionate environmental requirements into relevant supplier qualification, contracting and periodic-review activities. Reporting will distinguish between approved templates, obligations accepted by suppliers and reviews actually completed. Supplier engagement will be prioritised using expenditure, estimated emissions and supply criticality, with actual coverage reported annually.

UK Manufacturing and Local Production

Crescent Pharma Limited will evaluate lower-emission supply options through appropriately approved manufacturers, including UK suppliers and related companies where relevant. Assessments will consider available production, energy, yield, packaging and logistics information. Geographic proximity alone will not be treated as proof of a lower overall footprint. Changes remain subject to technical, regulatory, quality and continuity-of-supply requirements.

Warehousing Consolidation and Inventory Positioning

Crescent Pharma Limited will assess the overall environmental effect of its inventory-positioning and warehouse-network changes, including relevant changes associated with Sheffield. The assessment will consider inter-site transfers, site energy, temporary operational overlap, customer delivery routes, vehicle utilisation and changes in business volumes. Carbon savings will not be claimed solely from a reduction in warehouse numbers or individual journeys.

Freight Consolidation, Vehicle Utilisation and Route Optimisation

Crescent Pharma Limited has introduced measures to improve freight consolidation, vehicle utilisation and delivery planning across its distribution activities. These measures include consolidating shipments where possible, improving pallet and vehicle-fill rates, reducing part-load movements, coordinating delivery frequencies and using route-planning information to minimise unnecessary mileage and empty running.

Inventory planning and warehouse-management systems are used to support more efficient stock allocation and transport scheduling. Where practical, Crescent Pharma Limited also seeks to reduce intermediate movements by arranging more direct transportation between the supplying location, distribution centre and customer.

These activities are undertaken without compromising required delivery times, medicine availability, product security or the conditions required for the safe and compliant transportation of medicinal products.

Lower-Carbon Temperature-Controlled Logistics

Crescent Pharma Limited works with appropriately qualified and GDP-compliant logistics providers to identify lower-carbon transportation options for ambient and temperature-controlled medicinal products.

As part of logistics-provider selection and review, Crescent Pharma Limited considers providers' fleet efficiency, route-optimisation capability, vehicle utilisation, environmental performance and use of lower-emission vehicles or alternative fuels where these are operationally viable. Crescent Pharma Limited also seeks to minimise unnecessary temperature-controlled journeys through shipment consolidation and effective stock planning.

Any lower-carbon logistics arrangement must continue to meet Crescent Pharma Limited's established GDP requirements, including validated transport conditions, temperature monitoring, security, traceability, deviation management and protection of product quality throughout the distribution process.

Packaging Optimisation and Material Reduction

Crescent Pharma Limited reviews primary, secondary and tertiary packaging arrangements to identify opportunities to reduce unnecessary packaging material and improve transport and storage efficiency.

This includes consideration of appropriately sized shipping cases, more efficient pallet configurations, reduced use of stretch film and secondary materials and opportunities to reduce packaging weight or volume. Improved packaging and pallet utilisation can also increase the number of packs carried per vehicle or pallet and thereby reduce transportation requirements.

Any change affecting pharmaceutical packaging is managed through the appropriate pharmaceutical quality system and change-control process. Packaging reductions will only be implemented where they remain compatible with:

- the applicable Marketing Authorisation;
- GMP and GDP requirements;
- product stability and shelf life;
- tamper-evidence and serialisation requirements;
- product identification and information requirements;
- safe transportation and storage; and
- patient safety.

Where required, packaging changes are supported by technical assessment, stability data, supplier qualification and regulatory approval before implementation.

Site Energy Efficiency

Crescent Pharma Limited will review energy use across its in-boundary offices, warehouses and other controlled facilities. Reviews will prioritise lighting, heating, ventilation, building efficiency, metering and equipment charging. Completed improvements will be identified by site and implementation date, with measured energy savings where supported. Manufacturing equipment operated by other companies will not be presented as the Company's own equipment.

On-Site Solar Generation and Renewable Electricity

Crescent Pharma Limited will assess on-site solar generation and qualifying renewable-electricity procurement where it controls the relevant site or supply arrangement. Any installation reported as operational will be identified by location, commissioning date and ownership or contractual entitlement. Generated electricity, self-consumption, exports and renewable electricity purchased will be reported separately.

Digital and Paperless Operations

Crescent Pharma Limited has implemented digital systems across a wide range of business activities, including human resources, finance, supply-chain management, customer management and quality-management processes.

The use of cloud-based platforms, electronic records, digital workflows and electronic quality-management systems reduces reliance on printed documentation, physical document storage and office consumables. This is supported by Crescent Pharma Limited's Clear Desk Policy and the reduction of shared printing equipment to approximately one printer per floor.

These systems also support improved data visibility, inventory planning, document control and remote collaboration, which can contribute to reductions in waste, unnecessary stockholding and business travel.

Business Travel and Remote Collaboration

Crescent Pharma Limited's business-travel arrangements encourage employees to use video conferencing and remote collaboration where a physical meeting is not necessary. Where business travel is required, employees are encouraged to consider rail travel, public transport and car sharing before personal vehicle use or air travel, where practical.

Travel decisions continue to take account of operational requirements, employee safety, cost, journey duration and the need to maintain effective oversight of suppliers, manufacturing sites and regulated activities.

Waste and Resource Management

Waste segregation and recycling arrangements have been strengthened across Crescent Pharma Limited sites through the provision of dedicated waste containers, improved signage and increased employee awareness.

Crescent Pharma Limited seeks to reduce waste at source, improve recycling rates and minimise avoidable destruction of materials and finished products through improved forecasting, inventory control, stock rotation and warehouse management. Pharmaceutical and hazardous waste continues to be managed through appropriately authorised contractors and in accordance with applicable legal, environmental and product-security requirements.

Measurement and Continuous Improvement

Crescent Pharma Limited will continue to monitor these initiatives and assess their contribution to reductions in greenhouse gas emissions. Where reliable quantified carbon savings are not yet available, Crescent Pharma Limited will develop appropriate performance indicators and report progress through subsequent annual Carbon Reduction Plans.

Supporting evidence will be retained where applicable, including contractual requirements, freight and vehicle-utilisation information, warehouse-transfer records, packaging change controls, energy invoices, site-consumption records, equipment-upgrade documentation and renewable-generation data.

Future Carbon Reduction Initiatives

Crescent Pharma Limited has identified the following priority workstreams for further reducing greenhouse gas emissions across its operations, purchased goods and services, supply chain and distribution activities.

The programme is intended to move progressively from general environmental improvement to measured carbon reduction, with priority given to areas that are material to the Company's greenhouse gas footprint and where Crescent Pharma Limited can exercise direct control or meaningful influence.

Each workstream will be supported by appropriate baseline information, accountable ownership and measurable performance indicators. Projects requiring capital expenditure will remain subject to technical and financial approval.

Implementation will remain subject to technical feasibility, regulatory requirements, available infrastructure and commercial viability. No initiative will be implemented where it could compromise the applicable Marketing Authorisation, GMP, GDP, product quality, product stability, employee or patient safety, or continuity of medicine supply.

Where relevant, these measures will also be applied in the performance of NHS and other public-sector contracts.

Renewable Electricity Procurement

Crescent Pharma Limited will progressively increase the proportion of electricity obtained from qualifying renewable sources across operations within its reporting boundary.

The Company's current targets are:

- at least 10% renewable electricity by 2029;
- at least 50% renewable electricity by 2035; and
- 100% renewable electricity by 2050.

At locations where Crescent Pharma Limited controls the electricity contract, renewable electricity tariffs and other credible renewable-energy purchasing arrangements will be evaluated at contract renewal.

At leased or shared locations where electricity procurement is controlled by a landlord or managing agent, the Company will engage with the relevant party to determine whether renewable electricity can be introduced or increased.

Progress will be measured using actual electricity consumption and evidenced renewable electricity generation or procurement, rather than by the number or percentage of sites using renewable energy.

On-Site Renewable Energy Generation

Crescent Pharma Limited will assess opportunities for solar photovoltaic generation at locations within its operational boundary where the Company has sufficient control over the property and electricity supply.

Assessments will consider electricity consumption, operational demand, roof condition, structural suitability, landlord approval, grid capacity, investment requirements and anticipated environmental and financial return.

Where installations proceed, the Company will record electricity generated, consumed on site and exported to the grid. Opportunities for battery storage and the use of on-site generation to support electric-vehicle charging or other site demand will also be evaluated where technically and commercially viable.

Progress will be measured through installed capacity, electricity generated, percentage consumed on site and associated reduction in purchased grid electricity.

Energy Efficiency and Site Infrastructure

Crescent Pharma Limited will undertake energy-efficiency reviews across the offices, warehouses and other facilities within its operational-control boundary.

Reviews will consider:

lighting and occupancy controls; electricity sub-metering; heating, ventilation and air-conditioning operating schedules; building-management systems; preventative maintenance; insulation and building fabric; heatrecovery opportunities; and replacement of older equipment with more energy-efficient alternatives at the appropriate point in its operating life.

Energy-saving changes affecting controlled pharmaceutical environments will continue to be managed through the appropriate engineering, qualification and change-control processes.

Manufacturing facilities and manufacturing equipment operated by other companies will not be presented as Crescent Pharma Limited's own operational emissions. Where manufacturing is purchased by Crescent Pharma Limited, environmental performance will instead be addressed through supplier engagement and the relevant Scope 3 workstream.

Progress will be measured through site energy consumption, approved efficiency projects and, where practical, measured kWh and tCO_2e savings.

Company Vehicles and Workplace Charging

Crescent Pharma Limited will progressively transition company-provided vehicles towards lower-emission technologies as vehicles reach appropriate replacement points.

Fully electric vehicles will be the default replacement option where operationally suitable. Plug-in hybrid vehicles will be used only where a fully electric vehicle cannot reasonably meet the operational requirements of the role, with exceptions periodically reviewed.

Vehicles will not ordinarily be replaced prematurely solely for carbon-reduction purposes where doing so would result in unnecessary cost or asset disposal.

Workplace charging facilities will be assessed at appropriate locations, taking account of electrical capacity, property arrangements, employee demand and operational requirements.

Progress will be measured through fleet composition, vehicle replacement decisions, fuel consumption and the proportion of company vehicles using lower-emission technology.

Business Travel and Employee Commuting

The Company will continue to reduce avoidable business travel through video conferencing and remote collaboration where physical attendance is not necessary.

Where travel is required, rail, public transport and car sharing will be encouraged ahead of personal vehicle use or air travel where this is practical and consistent with operational requirements.

Crescent Pharma Limited will improve its understanding of employee commuting through periodic workforce surveys or equivalent analysis. Opportunities including workplace charging, car sharing, cycle-to-work arrangements and improved communication of public-transport options will be considered according to site need and employee demand.

Business-travel and commuting initiatives will continue to take account of employee safety, journey practicality and the need to maintain appropriate oversight of regulated suppliers, manufacturing partners and pharmaceutical operations.

Progress will be measured through business-travel emissions, mileage information, fleet data and periodic commuting information.

Employee Awareness and Engagement

Environmental awareness will continue to form part of employee induction and internal communications.

Additional role-specific awareness will be directed towards employees whose decisions materially influence the Company's emissions, particularly those involved in procurement, supply-chain planning, logistics, facilities, warehousing and distribution, quality and regulatory affairs, and capital expenditure.

Employees will also be encouraged to identify practical opportunities to reduce waste, energy consumption, unnecessary travel and inefficient working practices.

Supplier and CMO Environmental Engagement

Crescent Pharma Limited will progressively strengthen environmental engagement with suppliers, contract manufacturing organisations, logistics providers and other material service providers.

Supplier qualification, onboarding and periodic-review processes will increasingly consider:

the supplier's environmental policy and objectives; greenhouse gas measurement and reduction commitments; renewable-energy use; transport and distribution arrangements; relevant environmental certifications; and the supplier's ability to provide reliable emissions information.

Engagement will be prioritised according to a combination of estimated emissions impact, expenditure, purchase volume, supply criticality and the Company's ability to influence the supplier.

Priority suppliers may be requested to provide organisational emissions information, product-related carbon information, Carbon Reduction Plans or other evidence of environmental improvement.

Environmental factors will continue to be considered alongside pharmaceutical quality, regulatory compliance, technical capability, security of supply, service and commercial requirements.

Lower-Carbon Sourcing

Crescent Pharma Limited will review opportunities to reduce emissions associated with the sourcing of active pharmaceutical ingredients, excipients, packaging materials and finished pharmaceutical products.

Where equivalent, compliant and commercially viable options are available, Crescent Pharma Limited will consider:

- sourcing from locations closer to the point of manufacture or supply;
- increasing the use of suppliers with credible carbon-reduction programmes;
- obtaining improved supplier-specific emissions information;
- consolidating purchases and deliveries;
- reducing unnecessary expedited transportation;
- increasing the use of recycled or recyclable materials where technically suitable.

All changes will remain subject to supplier qualification, technical assessment, quality approval, regulatory requirements, validation and continuity-of-supply considerations.

UK Manufacturing and Packaging Supply Options

Crescent Pharma Limited will continue to assess opportunities to source the manufacture or packaging of suitable products from appropriately approved UK manufacturers, including related companies and independent contract manufacturing organisations where appropriate.

Local production may reduce reliance on long-distance international freight, shorten supply chains, improve responsiveness and strengthen continuity of supply. Opportunities will be assessed on a product-by-product basis, considering available manufacturing capability, capacity, technical-transfer requirements, regulatory approval, validation, cost, quality and supply resilience.

Where a suitable product is transferred to UK manufacture or packaging, Crescent Pharma Limited will seek to assess the effect on transportation requirements and associated greenhouse gas emissions.

Freight Consolidation and Transport Optimisation

Crescent Pharma Limited will continue to improve transport efficiency through shipment consolidation, increased pallet and vehicle utilisation, reduction of avoidable part-load movements, coordinated delivery schedules and improved route planning.

Supply-chain and logistics teams will consider direct movements from supplying locations where appropriate, reduced reliance on avoidable expedited freight, collaboration with logistics providers to reduce empty running and improved use of shipment data.

These improvements will not compromise customer service requirements, medicine availability, product security or required transport conditions.

Progress will be measured using appropriate indicators including shipment volumes, pallet utilisation, and vehicle utilisation

Lower-Carbon Temperature-Controlled Distribution

Crescent Pharma Limited will engage with qualified logistics providers to identify lower-carbon options for ambient and temperature-controlled pharmaceutical distribution.

This may include the use of more efficient vehicles, electric or lower-emission delivery fleets, alternative fuels, improved refrigeration technology, better route planning and increased shipment consolidation.

Any new logistics arrangement must remain compliant with GDP and Crescent Pharma Limited's approved transport requirements. Appropriate qualification or validation, temperature monitoring, security, traceability and deviation-management controls will be maintained throughout the transportation process.

Warehousing and Inventory Consolidation

Crescent Pharma Limited will continue the consolidation and optimisation of fast-moving stock within the Sheffield Distribution Centre where this reduces inter-site transfers and supports efficient customer fulfilment.

The programme will seek to:

- position fast-moving products closer to the principal point of dispatch;
- reduce repeated stock movements between warehouses;
- minimise duplicate handling and storage;
- improve vehicle and pallet utilisation;
- support more direct delivery routes;
- improve inventory visibility; and
- reduce the risk of excess or obsolete stock.

Crescent Pharma Limited will review transfer data, vehicle movements, stock profiles and customer demand to measure whether the programme is reducing inter-site mileage and associated emissions.

The broader warehouse network will also be periodically reviewed to determine whether stock is held in the most operationally and environmentally efficient location.

Packaging Optimisation

Crescent Pharma Limited will undertake a structured review of primary, secondary and tertiary packaging to identify opportunities to reduce material use, packaging weight and transport volume.

Potential initiatives include:

- reducing unnecessary secondary and tertiary packaging;
- improving carton and shipper-case dimensions;
- increasing pallet density;
- reducing the use of plastic stretch film;
- using recyclable materials where suitable;
- increasing recycled content where quality requirements permit;
- working with suppliers to reduce delivery packaging; and
- assessing reusable pallets, containers or transit packaging.

Packaging changes will only be implemented following appropriate assessment through Crescent Pharma Limited's pharmaceutical quality system. Where applicable, changes will be subject to change control, technical assessment, stability considerations, validation and regulatory approval.

No packaging reduction will be implemented where it could compromise product protection, tamper evidence, serialisation, labelling, stability, safe transportation, patient information or patient safety.

Waste Prevention and Circularity

Crescent Pharma Limited will continue to improve waste segregation and recycling while placing greater emphasis on preventing waste at source.

Future priorities will include:

- reducing obsolete and expired stock through improved forecasting;
- strengthening stock rotation and first-expiry-first-out controls;
- reducing unnecessary product and material destruction;
- improving segregation of recyclable materials;
- reviewing supplier packaging take-back arrangements;
- identifying opportunities to reuse pallets and suitable transit materials;
- reducing single-use materials where compatible with GMP and safety requirements; and
- improving the measurement of waste by type and disposal route.

Pharmaceutical, controlled, hazardous and confidential waste will continue to be handled through appropriately authorised contractors and in accordance with applicable legal, quality and security requirements.

Pharmaceutical Safeguards

No initiative will be implemented where it would compromise the applicable Marketing Authorisation, GMP, GDP, product quality, stability, storage or transport conditions, patient information, tamper evidence, serialisation where applicable, employee safety or continuity of medicine supply.

Relevant changes will undergo the required quality-system change control, technical assessment, qualification, validation and regulatory approval.

Carbon Reduction Delivery Programme

Crescent Pharma Limited will prioritise carbon-reduction activity according to the materiality of the relevant emissions source, the Company's degree of control or influence, technical feasibility, expected carbon benefit, cost, regulatory impact and implications for medicine supply. The Company will favour measures that produce demonstrable absolute emissions reductions. Where reliable carbon savings cannot yet be calculated, relevant operational indicators will be used until sufficient data become available.

Each material workstream will have an accountable functional owner, a documented starting position, a delivery milestone and evidence of implementation. Capital projects require separate technical and financial approval.

Workstream	Owner	Delivery milestone and evidence
Site energy and renewable electricity	Facilities and Finance	Complete a review of every in-boundary operating site by 31 March 2027. Record site kWh, approved projects and measured outcomes.
Sheffield and warehouse-network optimisation	Operations and Logistics	Complete a consistent before-and-after assessment by 31 March 2027, including energy, transfers, routes and volumes.
Freight and GDP logistics	Logistics and Procurement	Map material providers and lanes by 31 March 2027. Track mode, distance, weight, utilisation and avoidable expedited freight.
Supplier emissions and manufacturing purchases	Procurement, Quality and Finance	Identify material suppliers by 31 December 2026; issue prioritised data requests and report engagement coverage by 31 March 2027.
Packaging and avoidable stock destruction	Operations, Procurement and Quality	Prioritise projects by 31 March 2027 using material weights, stock-loss causes and disposal records.
Vehicles, travel and commuting	Finance, HR and Operations	Document fleet replacement requirements and reporting-year travel/commuting methods by 31 March 2027.
Expanded Scope 3 reporting	CRP coordinator, Finance and Procurement	Screen all 15 categories by 31 December 2026 and prepare the applicable expanded reporting before 1 April 2027.

Carbon Measurement and Governance

The Board has overall accountability for this plan. The designated CRP coordinator will maintain the calculation register, project register, supporting evidence and annual publication timetable. Finance will coordinate the legal-entity reconciliation and calculation review. Facilities and Operations will provide energy, asset and refrigerant information; Logistics will provide transport and storage records; HR will provide workforce and commuting information; Procurement will coordinate supplier data; and Quality/Regulatory will assess changes affecting medicinal products and regulated operations.

Progress, material data gaps and overdue actions will be reviewed quarterly. The Board will approve material target or boundary changes and the final Carbon Reduction Plan. The public plan, Evergreen submission and relevant tender declarations will be reconciled for entity, reporting period, emissions, commitments and approval status. A readiness review will be completed by 31 March 2027 for the applicable new NHS requirements. The completed 2026 inventory and next annual Carbon Reduction Plan will be published by 30 June 2027. Approved and superseded versions, supporting data and approval records will be retained.

Evergreen and Tender Reporting

The Company will maintain an active Evergreen assessment where required for its tender route. The Commercial team will check the assessment requirements and any minimum maturity level in the relevant tender documents. This plan does not assert an unverified Evergreen score.

Declaration and Approval

This Carbon Reduction Plan has been completed in accordance with PPN 006 and the associated guidance and reporting standard. Emissions have been recorded using the GHG Protocol Corporate Accounting and Reporting Standard and appropriate Government conversion factors or other documented factors identified in the methodology. Scope 1 and Scope 2 have been reported in accordance with the applicable environmental reporting guidance, including SECR reporting principles. The required Scope 3 categories have been reported in accordance with the Carbon Reduction Plan reporting standard and the Corporate Value Chain (Scope 3) Standard.

This Carbon Reduction Plan has been reviewed and approved by the Board of Directors of Crescent Pharma Limited. The Board approves the company-specific commitments, responsibilities and delivery milestones stated in the plan.

Signed on behalf of Crescent Pharma Limited:

Approved By: Samie Aldoori, Director
Date: 22 September 2026
Next Compliance Review Date: March 2027
Next NHS Compliance Update Date: April 2027
Next Annual Publication Date: June 2027